1
|
Abstract
The increasing complexity of the pathways implicated in the pathogenesis of familial amyotrophic lateral sclerosis (ALS) has stimulated intensive research in many directions. Genetic analysis of familial ALS has yielded six loci and one disease gene (SOD1), initially suggesting a role for free radicals in the disease process, although the mechanisms through which the mutant exerts toxicity and results in selective motor neuron death remain uncertain. Numerous studies have focused on structural elements of the affected cell, emphasizing the role of neurofilaments and peripherin and their functional disruption in disease. Other topics examined include cellular homeostasis of copper and calcium, particularly in the context of oxidative stress and the processes of protein aggregation, glutamate excitotoxicity, and apoptosis. It has become evident that there is considerable interplay between these mechanisms and, as the role of each is established, a common picture may emerge, enabling the development of more targeted therapies. This study discusses the main areas of investigation and reviews the findings.
Collapse
Affiliation(s)
- Collette K Hand
- Centre for Research in Neuroscience, McGill University, and Montréal General Hospital Research Institute (L7-224), 1650 Cedar Avenue, Montréal, Quebec H3G 1A4, Canada
| | | |
Collapse
|
2
|
Hand CK, Khoris J, Salachas F, Gros-Louis F, Lopes AAS, Mayeux-Portas V, Brown, Jr. RH, Meininger V, Camu W, Rouleau GA. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2002; 70:251-6. [PMID: 11706389 PMCID: PMC384894 DOI: 10.1086/337945] [Citation(s) in RCA: 103] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2001] [Accepted: 10/05/2001] [Indexed: 11/03/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is an adult-onset degenerative disorder characterized by the death of motor neurons in the cortex, brain stem, and spinal cord. Despite intensive research the basic pathophysiology of ALS remains unclear. Although most cases are sporadic, approximately 10% of ALS cases are familial (FALS). Mutations in the Cu/Zn superoxide dismutase (SOD1) gene cause approximately 20% of FALS. The gene(s) responsible for the remaining 80% of FALS remain to be found. Using a large European kindred without SOD1 mutation and with classic autosomal dominant adult-onset ALS, we have identified a novel locus by performing a genome scan and linkage analysis. The maximum LOD score is 4.5 at recombination fraction 0.0, for polymorphism D18S39. Haplotype analysis has identified a 7.5-cM, 8-Mb region of chromosome 18q21, flanked by markers D18S846 and D18S1109, as a novel FALS locus.
Collapse
Affiliation(s)
- Collette K. Hand
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - Jawad Khoris
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - François Salachas
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - François Gros-Louis
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - Ana Amélia Simões Lopes
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - Veronique Mayeux-Portas
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - Robert H. Brown, Jr.
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - Vincent Meininger
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - William Camu
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| | - Guy A. Rouleau
- Centre for Research in Neuroscience, McGill University and the Montréal General Hospital Research Institute, Montréal; UNCD Molecular Unit, INSERM V 336, Institute of Biology, and Department of Neurology, Hôpital Gui de Chauliac, Montpellier, France; Service de Neurologie, Division Mazarin, Hôpital Pitie Salpetriere, Paris; and Massachusetts General Hospital, Boston
| |
Collapse
|
4
|
Orrell RW, King AW, Lane RJ, de Belleroche JS. Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis. J Neurol Sci 1995; 132:126-8. [PMID: 8543936 DOI: 10.1016/0022-510x(95)00129-p] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Neurotrophic factors, such as ciliary neurotrophic factor (CNTF), have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS), a human neurodegenerative disease primarily of upper and lower motor neurones. A null mutation of the CNTF gene has recently been described. The mutation is an intronic point mutation (G to A) which generates a new splice acceptor site and a 4 bp insertion within the CNTF coding region, and prevents the expression of the normal protein. We investigated this as a candidate gene in 49 families with ALS, where the genetic component may be expected to be strongest. 65% were normal homozygotes, and 35% were heterozygotes for the mutation. No mutant homozygotes were detected. The absence of CNTF protein expression associated with the homozygote mutation does not appear to be of major significance in the development of ALS.
Collapse
Affiliation(s)
- R W Orrell
- Department of Biochemistry, Charing Cross and Westminister Medical School, London, UK
| | | | | | | |
Collapse
|
5
|
Virgo L, de Belleroche J. Induction of the immediate early gene c-jun in human spinal cord in amyotrophic lateral sclerosis with concomitant loss of NMDA receptor NR-1 and glycine transporter mRNA. Brain Res 1995; 676:196-204. [PMID: 7796170 DOI: 10.1016/0006-8993(95)00052-r] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The aetiology of the sporadic form of amyotrophic lateral sclerosis (ALS) is poorly understood although abnormalities in glutamate and glycine transport have been implicated which both could contribute to a neurodegenerative process mediated through the N-methyl-D-aspartate (NMDA) receptor. In this study we have used in situ hybridization to investigate whether any changes in the expression of NMDA receptors, the glycine transporter or glutamate-mediated injury responses are detectable in ALS. Two immediate early genes were investigated as markers of neuronal injury responses, c-jun and zif-268, both constitutively expressed in the spinal cord. Levels of c-jun mRNA were most abundant in intermediate grey and layer IX of the ventral horn containing motor neurones. This pattern was markedly changed in ALS with large increases (2-3 fold) in c-jun mRNA occurring in dorsal and ventral horn. The marked increase in c-jun mRNA was also substantiated by slot blot analysis of tissue homogenates of spinal cord and a parallel induction of zif-268 mRNA was also seen. NMDA receptor NR-1 mRNA was widely distributed in control spinal cord with the highest concentrations occurring in layers IX, X, intermediate grey and dorsal horn. The ALS cases showed a selective decrease in the level of NR-1 mRNA in the ventral region (50%) whilst no significant decrease was detected in the dorsal region. Quantitation of tissue homogenates with dorsal and ventral regions combined also yielded a significant decrease of 40% which supports the analysis from in situ hybridization densitometry.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- L Virgo
- Department of Biochemistry, Charing Cross and Westminster Medical School, London, UK
| | | |
Collapse
|
6
|
Rosen DR, Sapp P, O'Regan J, McKenna-Yasek D, Schlumpf KS, Haines JL, Gusella JF, Horvitz HR, Brown RH. Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromosome 21 microsatellite DNA markers. AMERICAN JOURNAL OF MEDICAL GENETICS 1994; 51:61-9. [PMID: 7913294 DOI: 10.1002/ajmg.1320510114] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Amyotrophic lateral sclerosis (ALS: Lou Gehrig's Disease) is a lethal neurodegenerative disease of upper and lower motorneurons in the brain and spinal cord. We previously reported linkage of a gene for familial ALS (FALS) to human chromosome 21 using 4 restriction fragment length polymorphism DNA markers [Siddique et al.: N Engl J Med 324:1381-1384, 1991] and identified disease-associated mutations in the superoxide dismutase (SOD)-1 gene in some ALS families [Rosen et al.: Nature 362:59-62, 1993]. We report here the genetic linkage data that led us to examine the SOD-1 gene for mutations. We also report a new microsatellite DNA marker for D21S63, derived from the cosmid PW517 [VanKeuren et al.: Am J Hum Genet 38:793-804, 1986]. Ten microsatellite DNA markers, including the new marker D21S63, were used to reinvestigate linkage of FALS to chromosome 21. Genetic linkage analysis performed with 13 ALS families for these 10 DNA markers confirmed the presence of a FALS gene on chromosome 21. The highest total 2-point LOD score for all families was 4.33, obtained at a distance of 10 cM from the marker D21S223. For 5 ALS families linked to chromosome 21, a peak 2-point LOD score of 5.94 was obtained at the DNA marker D21S223. A multipoint score of 6.50 was obtained with the markers D21S213, D21S223, D21S167, and FALS for 5 chromosome 21-linked ALS families. The haplotypes of these families for the 10 DNA markers revealed recombination events that further refined the location of the FALS gene to a segment of approximately 5 megabases (Mb) between D21S213 and D21S219.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D R Rosen
- Day Neuromuscular Research Laboratory, Massachusetts General Hospital, Charlestown 02129-2060
| | | | | | | | | | | | | | | | | |
Collapse
|